Ligand id: 6598

Name: physostigmine

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: physostigmine

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 44.81
Molecular weight 275.16
XLogP 1.87
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used in the treatment of glaucoma, in which it can be applied topically to the conjunctiva. Also used in the treatment of severe anticholinergic toxicity. There is no information regarding approval for clinical use of this drug on the US FDA or European Medicines Agency websites. Individual national approval agencies may have granted marketing authorisation.
Mechanism Of Action and Pharmacodynamic Effects
Inhibits acetylcholinesterase. The reduced breakdown of acetylcholine and resulting increase in acetylcholine at the synapse leads to stimulation of nicotinic acetylcholine receptors.
External links